Sanofi announced an agreement to acquire Blueprint Medicines Corporation for $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR for the achievement of future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The upfront offer price provides a premium of approximately 27% over Blueprint's closing price on May 30, 2025, and approximately 34% over the 30 trading days volume weighted average price as of the same date.
The acquisition includes AYVAKIT (avapritinib), a medicine approved in the U.S. and the EU for systemic mastocytosis, and a promising advanced and early-stage immunology pipeline, including elenestinib and BLU-808. Sanofi expects to complete the acquisition in the third quarter of 2025, subject to customary closing conditions and regulatory approvals. This strategic move is expected to enhance Sanofi’s immunology pipeline and accelerate the global reach of Blueprint’s mast cell-targeted therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.